Clinical Trials Browser

Colorectal Neoplasms × enfortumab vedotin × 90 days × Clear all

NCT06553885 2026-04-01

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Colorectal Neoplasms